WAVE Life Sciences Ltd. $WVE Stock Holdings Boosted by Squarepoint Ops LLC

Squarepoint Ops LLC boosted its position in WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 68.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,541,442 shares of the company's stock after purchasing an additional 1,029,052 shares during the quarter. Squarepoint Ops LLC owned about 1.29% of WAVE Life Sciences worth $14,766,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its holdings in shares of WAVE Life Sciences by 645.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company's stock valued at $38,000 after buying an additional 1,942 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in WAVE Life Sciences by 1,441.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company's stock worth $73,000 after buying an additional 9,284 shares in the last quarter. Tower Research Capital LLC TRC increased its position in WAVE Life Sciences by 44.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company's stock valued at $76,000 after acquiring an additional 3,609 shares during the period. AlphaGrep UK Ltd acquired a new stake in WAVE Life Sciences in the 2nd quarter valued at approximately $78,000. Finally, Prudential Financial Inc. acquired a new stake in WAVE Life Sciences in the 2nd quarter valued at approximately $80,000. 89.73% of the stock is owned by institutional investors and hedge funds.

WAVE Life Sciences Trading Down 2.0%

Shares of WAVE Life Sciences stock opened at $4.81 on Thursday. The company's 50-day moving average price is $5.58 and its two-hundred day moving average price is $7.35. WAVE Life Sciences Ltd. has a 52 week low of $4.64 and a 52 week high of $21.73. The stock has a market cap of $947.81 million, a PE ratio of -4.41 and a beta of -1.30.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The business had revenue of $2.27 million for the quarter, compared to the consensus estimate of $7.45 million. WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. On average, equities analysts predict that WAVE Life Sciences Ltd. will post -1.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Wells Fargo & Company boosted their price target on WAVE Life Sciences from $13.00 to $14.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of WAVE Life Sciences in a report on Friday, July 17th. Wedbush cut their price objective on shares of WAVE Life Sciences from $15.00 to $12.00 and set an "outperform" rating on the stock in a research note on Friday, July 31st. New Street Research set a $13.00 price objective on shares of WAVE Life Sciences in a report on Thursday, June 11th. Finally, Zacks Research lowered shares of WAVE Life Sciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Fourteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $22.31.

Insider Activity at WAVE Life Sciences

In other WAVE Life Sciences news, Director Heidi L. Wagner sold 7,000 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total value of $42,070.00. Following the transaction, the director owned 44,930 shares of the company's stock, valued at approximately $270,029.30. This represents a 13.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Adrian Rawcliffe sold 12,700 shares of the company's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 23,564 shares of company stock valued at $132,476. Company insiders own 24.30% of the company's stock.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.

Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.